Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 6
Submit an article Journal homepage
242
Views
67
CrossRef citations to date
0
Altmetric
Review

Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer

Martin H Fenner Charité School of Medicine, Department of Oncology and Haematology, Humboldt University, Schumannstr. 20/21, 10117 Berlin, Germany. [email protected]
&
Elena Elstner Charité School of Medicine, Department of Oncology and Haematology, Humboldt University, Schumannstr. 20/21, 10117 Berlin, Germany. [email protected]
Pages 557-568 | Published online: 11 Jul 2005

Bibliography

  • KERSTEN S, DESVERGNE B, WAHLI W: Roles of PPARs in health and disease. Nature (2000) 405:421–424.
  • •Review of PPARs.
  • KOEFFLER HP: Peroxisome proliferator- activated receptor-y and cancers. Clin. Cancer Res. (2003) 9:1–9.
  • ••Review of the role of PPAR-y in cancer.
  • PANIGRAHY D, SHEN LQ, KIERAN MW, KAIPAINEN A: Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Investig. Drugs (2003) 12:1925–1937.
  • ••Excellent review of TZDs as anticancerdrugs.
  • THEOCHARISA S, MARGELI A, KOURAKILIS G: Peroxisome proliferator activated receptor-y ligands as potent antineoplastic agents. Curr. Med. Chem. AntiCanc. Agents (2003) 3:239–251.
  • GROMMES C, LANDRETH GE, HENEKA MT: Antineoplastic effects of peroxisome proliferator-activated receptor-y agonists. Lancet Once]. (2004) 5:419–429.
  • MICHALIK L, DESVERGNE B, WAHLI W: Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev Cancer (2004) 4:61–70.
  • ••Review of the role of PPAR-y in cancer.
  • RUMI MA, ISHIHARA S, KAZUMORI H, KADOWAKI Y, KINOSHITA Y: Can PPAR-y ligands be used in cancer therapy? Curr. Med. Chem. AntiCanc. Agents (2004) 4:465–77.
  • HAYS T, RUSYN I, BURNS AM et al: Role of peroxisome proliferator-activated receptor-a (PPAR-a) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinegenesis (2005) 26:219–227.
  • ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 347:645–650.
  • ••First identification of a PPAR.
  • TUGWOOD JD, ISSEMANN I, ANDERSON RG, BUNDELL KR, McPHEAT WL, GREEN S: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. (1992) 11:433–9.
  • ISSEMANN I, PRINCE RA, TUGWOOD JD, GREEN S: The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mel Endocrine]. (1993) 11:37–47.
  • STAELS B, DALLONGEVILLE J, AUWERX J, SCHOONJANS K, LEITERSDORF E, FRUCHART JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 98:2088–93.
  • SCHMIDT A, ENDO N, RUTLEDGE SJ, VOGEL R, SHINAR D, RODAN GA: Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mel Endocrine]. (1992) 6:1634–1641.
  • MICHALIK L, DERVERGNE B, TAN NS et al: Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)-a and PPAR-13 mutant mice. I Cell Biel (2001) 154:799–814.
  • HE TC, CHAN TA, VOGELSTEIN B, KINZLER KW: PPAR-.5 is an APC-regulated target of nonsteroidal anti- inflammatory drugs. Cell (1999) 99:335–345.
  • PARK BH, VOGELSTEIN B, KINZLER KW: Genetic disruption of PPAR8 decreases the tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sri. USA (2001) 98:2598–2603.
  • HARMAN FS, NICOL CJ, MARIN HE, WARD JM, GONZALEZ FJ, PETERS JM: Peroxisome proliferator-activated receptor-8 attenuates colon carcinogenesis. Nat. Med. (2004) 10:481–483.
  • TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation of adipogenesis in fibroblasts by PPAR-y2, a lipid-activated transcription factor. Cell (1994) 79:1147–1156.
  • LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKINSON WO, WILLSON TM, KLIEWER SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-y (PPAR-y). J. Biol. Chem. (1995) 270:12953–12956.
  • •First description of thiazolidinediones as PPAR-y ligands.
  • CHANG AY, WYSE BM, GILCHRIST BJ, PETERSON T, DIANI AR: Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes (1983) 32:830–838.
  • FAJAS L, AUBOEF D, RASPE E et al.: The organization, promoter analysis, and expression of the human PPAR-y gene. Biol. Chem. (1997) 272:18779–18789.
  • HU E, TONOTONOZ P, SPIEGELMAN BM: Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR-y and C/EBP-a. Proc. Natl. Acad. Sci. USA (1995) 92:9856–9860.
  • •PPAR-y induces adipocyte differentiation.
  • KLIEWER SA, LENHARD JM, WILLSON TM, PATEL I, MORRIS DC, LEHMANN JM: A prostaglandin j2 metabolite binds peroxisome proliferator-activated receptor-y and promotes adipocyte differentiation. Cell (1995) 83:813–819.
  • FORMAN BM, TON OTNOZ P, CHEN J, BRUN RP, SPIEGELMAN BM, EVANS RIVI: 15-Deoxy-812,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-y. Cell (1995) 83:803–812.
  • BERGER J, LEIBOWITCZ MD, DOEBBER TW etal.: Novel peroxisome proliferator-activated receptor (PPAR)-y and PPAR-8 ligands produce distinct biological effects. J. Biol. Chem. (1999) 274:6718–6725.
  • PLACE AE, SUH N, WILLIAMS CR et al.: The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumour growth in vivo. Clin. Cancer Res. (2003) 9:2798–2806.
  • QIN C, MORROW D, STEWART J et al.:A new class of peroxisome proliferator-activated receptor-y (PPAR-y) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indoly1)-1- (p-substituted phenyOmethanes. Mol. Cancer Ther. (2004) 3:247–260.
  • TONG WG, DING XZ, HENNIG R et al.: Leukotriene B4 receptor antagonist LY-293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin. Cancer Res. (2002) 8:3232–3242.
  • COPLAND JA, KURAKATA S, FUJIWARA K et al.: A novel high affinity PPAR-y agonist inhibits human anaplastic thyroid tumour growth. AACR Annual Meeting, Orlando, USA (2004)1B–17.
  • KOLLURI SK, CORR M, JAMES SY et al.: The (R)-enantiomer of the nonsteroidal anti-inflammatory drug etodolac binds retinoid X receptor and induces tumour-selective apoptosis. Proc. Nati Acad. Li. USA (2005) 102:2525–2530.
  • RIVAL Y, STENNEVIN A, PUECH L et al.: Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor-y ligands. Pharmacol. Exp. Ther. (2004) 311:467–75.
  • REGINATO MJ, BAILEY ST, KRAKOW SL et al.: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor-y-activating properties. J. Biol. Chem. (1998) 273:32679–84.
  • ELBRECHT A, CHEN Y, ADAMS A et al.: L-764406 is a partial agonist of human peroxisome proliferator-activated receptor-y. The role of Cys313 in ligand binding. Biol. Chem. (1999) 274:7913–7922.
  • OBERFIELD JL, COLLINS JL, HOLMES CP et al.: A peroxisome proliferator-activated receptor-y ligand inhibits adipocyte differentiation. Proc. Nati Acad. Li. USA (1999) 96:6102–6106.
  • DOGGRELL SA: Telmisartan - killing two birds with one stone. Expert Opin. Pharmacother. (2004) 5:2397–2400.
  • SCHUPP M, GINESTE R, CLEMENZ M et al.: PPAR-y activating angiotensin receptor blockers exhibit differential cofactor recruitment and induce a divergent gene expression profile in 3T3-L1 adipocytes. 3rd International Symposium on PPARS. Monte Carlo, Monaco (19–23 March 2005):11.
  • LJUNG B, BAMBERG K, DAHLLOF B et al.: AZ-242, a novel PPAR-a/y agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. (2002) 43:1855–1863.
  • GUO Q, SAHOO SP, WANG PR et al.: A novel peroxisome proliferator-activated receptor-a/y dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology (2004) 145:1640–1648.
  • DEVASTHALE PV, CHEN S, JEON Y et al.: Design and synthesis of N-1(4- methoxyphenoxy)carbonyll-N-114- [2- (5-methy1-2-pheny1-4-oxazolyflethoxylphenyllmethyllglycine [IVIuraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor-a/y dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem (2005) 48:2248–2250.
  • PICKAVANCE LC, BRAND CL, WASSERMANN K, WILDING JP: The dual PPAR-a/y agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. BE Pharmacol. (2005) 144:308–316.
  • LIU DC, ZANG CB, LIU HY, POSSINGER K, FAN SG, ELSTNER E: A novel PPAR-a/y dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol. SM. (2004) 25:1312–1319.
  • WESTIN S, KUROKAWA R, NOLTE RT et al.: Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature (1998) 395:199–202.
  • •Interactions of PPAR-y and RXR.
  • MIZUKAMI J, TANIGUCHI T: The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR-y and CBP. Biochem. Biophys. Res. Commun. (1997) 240:61–64.
  • NOLTE RT, WISELY GB, WESTIN S et al.: Ligand binding and co-activator assembly of the peroxisome proliferator-564 Expert Op/n. Investig. Drugs (2005) 14(6)
  • •• activated receptor-y. Nature (1998) 395:137–143.
  • BERGER JP: PPAR ligands and mechanisms: an update. 3rd International Symposium on PPARS. Monte Carlo, Monaco (19–23 March 2005):2.
  • TEMPLE KA, COHEN RN, WONDISFORD SR, YU C, DEPLEWSKI D, WONDISFORD FE: An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor-y (PPAR-y) binding and activation on some PPAR response elements. J. Biol. Chem. (2005) 280:3529–3540.
  • GE K, GUERMAH M, YUAN CX et al.: Transcription co-activator TRAP220 is required for PPAR-y2-stimulated adipogenesis. Nature (2002) 417:563–567.
  • WALLBERG AE, YAMAMURA S, MALIK S, SPEIGELMAN BM, ROEDER RG: Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through co-activator PGC-la. Mol. Cell (2003) 12:1137–1149.
  • PUIGSERVER P, ADELMANT G, WU Z et al.: Activation of PPAR-y co-activator-1 through transcription factor docking. Science (1999) 286:1368–1371.
  • ••Co-activator recruitment in PPAR-yactivation.
  • MUELLER E, DRORI S, AIYER A et al.:Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor-y isoforms. Biol. Chem. (2002) 277:41925–41930.
  • SHI Y, HON M, EVANS RIVI: The peroxisome proliferator-activated receptor-8, an integrator of transcriptional repression and nuclear receptor signalling. Proc. Nati Acad. Sri. USA (2002) 99:2613–2618.
  • YU C, MARKAN K, TEMPLE KA, DEPLEWSKI D, BRADY MJ, COHEN RN: The nuclear receptor corepressors NCoR and SMRT decrease PPAR-y transcriptional activity and repress 3T3-L1 adipogenesis. .1 Biol. Chem. (2005) 280:13600–13605.
  • PICARD F, KURTEV M, CHUNG N et al.: Sirtl promotes fat mobilization in white adipocytes by repressing PPAR-y. Nature (2004) 429:771–776.
  • FLOYD ZE, STEPHENS JM: Control ofperoxisome proliferator-activated receptor-y2 stability and activity by SUMOylation. Obes. Res. (2004) 12:921–928.
  • OHSHIMA T, KOGA H, SHIMOTOHNO K: Transcriptional activity of peroxisome proliferator-activated receptor-y is modulated by SUMO-1 modification../. Biol. Chem. (2004) 279:29551–29557.
  • SUCHANEK KM, MAY FJ, ROBINSON JA et al.: Peroxisome proliferator-activated receptor-a in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinog. (2002) 34:165–171.
  • SUCHANEK KM, MAY FJ, LEE WJ, HOLMAN NA, ROBERTS-THOMSON SJ: Peroxisome proliferator-activated receptor 13 expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin. Int. I Biochem. Cell Biol. (2002) 34:1051–1058.
  • STEPHEN RL, GUSTAFSSON MC, JARVIS M et al.: Activation of peroxisome proliferator-activated receptor-8 stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. (2004) 64:3162–3170.
  • CHAWLA A, BARAK Y, NAGY L, LIAO D, TONOTONOZ P, EVANS RIVI: PPAR-y dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. (2001) 7:48–52.
  • ROSSI A, KAPAHI P, NATOLI G et al.: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I-x13 kinase. Nature (2000) 403:103–8.
  • STRAUS DS, PASCUAL G, LI M et al.: 15-deoxy-8 12,14-prostaglandin J2 inhibits multiple steps in the NF-x13 signalling pathway. Proc. Natl. Acad. Sri. USA (2000) 97:4844–4849.
  • •15d-PGJ2 inhibits macrophage function in part independently of PPAR-y via NF-K13.
  • PALAKURTHI SS, AKTAS H, GRUBISICCHI LM, MORTENSEN RM, HALPERIN JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor-y and mediated by inhibition of translation initiation. Cancer Res. (2001) 61:6213–6218.
  • CLAY CE, MONJAZEB A, THORBURN J, CHILTON FH, HIGH KP: 15-Deoxy-812,14-prostaglandin J2-induced apoptosis does not require PPARy in breast cancer cells. J. Lipid Res. (2002) 43:1818–1828.
  • TURTURRO F, FRIDAY E, FOWLER R, SURIE D, WELBOURNE T: Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor-y-independent mechanism in breast cancer-derived cell lines. Clin. Cancer Res. (2004) 10:7022–7030.
  • LEA MA, SURA M, DESBORDES C: Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR)-y agonists and antagonists. AntiCancer Res. (2004) 24:2765–2771.
  • SEARGENT JM, YATES EA, GILL JH: GW-9662, a potent antagonist of PPAR-y, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR-y agonist rosiglitazone, independently of PPARy activation. BE Pharmacol. (2004) 143:933–937.
  • SHIAU CW, YANG CC, KULP SK et al.: Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bc1-xL/Bc1-2 functions independently of PPAR-y. Cancer Res. (2005) 65:1561–1569.
  • HUANG JW, SHIAU CW, YANG YT KF et al.: Peroxisome proliferator-activated receptor {y}-independent ablation of cyclin D1 by thiazolidenediones and their derivatives in breast cancer cells. Mol. Pharmacol. (2005) 67:1342–1348.
  • BRAISSANT 0, FOUFELLE F, SCOTTO C, DAUCA M, WAHLI W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-a, 13, and -yin the adult rat. Endocrinology (1996) 137:354–366.
  • JAIN S, PULIKURI S, ZHU Y et al.: Differential expression of the peroxisome proliferator-activated receptor-y (PPAR-y) and its co-activators steroid receptor co-activator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am. I Pathol. (1998) 153:349–354.
  • KILGORE MW, TATE PL, RAI S, SENGOKU E, PRICE TM: MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol. Endocrinol. (1997) 129:229–235.
  • ELSTNER E, WILLIAMSON EA, ZANG C et al.: Novel therapeutic approach: ligands for PPAR-y and retinoid receptors induce apoptosis in bc1-2-positive565 human breast cancer cells. Breast Cancer Res. Treat (2002) 74:155–65.
  • ELSTNER E, MUELLER C, KOSHIZUKA K et al: Ligands for peroxisome proliferator-activated receptor-y and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA (1998) 95:8806–8811.
  • ••The first paper describing the anticancereffects of PPAR-y ligands in vivo.
  • YANG Z, BAGHERI-YARMAND R, BALASENTHIL S et al: HER2 regulation of peroxisome proliferator-activated receptor-y (PPAR-y) expression and sensitivity of breast cancer cells to PPAR-y ligand therapy. Clin. Cancer Res. (2003) 9:3198–3203.
  • JIANG WG, DOUGLAS-JONES A, MANSEL RE: Expression of peroxisome-proliferator activated receptor-y (PPAR-y) and the PPAR-y co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int. J. Cancer (2003) 106:752–757.
  • BADAWI AF, BADR MZ: Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-y and levels of prostaglandin E2 and 15-deoxy-812,14-prostaglandin J2 in human breast cancer and metastasis. bit. .1 Cancer (2003) 103:84–90.
  • YEE LD, GUO Y, BRADBURY J, SUSTER S, CLINTON SK, SEEWALDT VL: The antiproliferative effects of PPAR-y ligands in normal human mammary epithelial cells. Breast Cancer Res. Treat (2003) 78:179–192.
  • IKEZOE T, MILLER CW, KAWANO S et al.: Mutational analysis of the peroxisome proliferator-activated receptor-y gene in human malignancies. Cancer Res. (2001) 61:5307–5310.
  • •Mutational analysis of PPAR-y in human cancers.
  • KROLL TG, SERRAF P, PECCIARINI L et al.: PAX8-PPARy1 fusion oncogene in human thyroid carcinoma. Science (2000) 289:1357–1360.
  • ••The first translocation involving PPAR-yin a human cancer.
  • POSCH MG, ZANG C, MUELLER W, LASS U, VON DEIMLING A, ELSTNER E: Somatic mutations in peroxisome proliferator-activated receptor-y are rare events in human cancer cells. Med. Sci. Montt. (2004) 10:BR250-BR254.
  • MEMISOGLU A, HANKINSON SE, MANS ON JE, COLDITZ GA, HUNTER DJ: Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor-y gene with breast cancer and body mass. Pharmacogenetics (2002) 12:597–603.
  • TONTONOZ P, SINGERS, FORMAN BM et al.: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor-y and the retinoid X receptor. Proc. Natl. Acad. Sci. USA (1997) 94:237–241.
  • MUELLER E, SARRAF P, TONTONOZ P et al.: Terminal differentiation of human breast cancer through PPAR-y. Mol. Cell (1998) 1:465–470.
  • ••Terminal differentiation and growthinhibition in breast cancer cells.
  • CLAY CE, NAMEN AM, ATSUMI G et al: Influence of J series prostaglandins on apoptosis and tumourigenesis of breast cancer cells. Carcinogenesis (1999) 20:1905–1911.
  • THEOCHARIS S, MARGELI A, VIELH P, KOUR'AKLIS G: Peroxisome proliferator-activated receptor-y ligands as cell-cycle modulators. Cancer Treat. Rev (2004) 30:545–554.
  • WANG C, FU M, D'AMICO M et al: Inhibition of cellular proliferation through Ix13 kinase-independent and peroxisome proliferator-activated receptor-y-dependent repression of cyclin Dl. Mol. Cell. Biol. (2001) 21:3057–3070.
  • YIN F, WAKINO S, LIU Z et al: Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem. Biophys. Res. Commun. (2001) 286:916–922.
  • WANG C, PATTABIRAMAN N, ZHOU JN et al.: Cyclin D1 repression of peroxisome proliferator-activated receptor-y expression and transactivation. Mol. Biol. (2003) 23:6159–6173.
  • FU M, RAO M, BOURAS T et al: Cyclin D1 inhibits peroxisome proliferator-activated receptor-{y}-mediated adipogenesis through histone deacetylase recruitment. Biol. Chem. (2005) 280:16934–16941.
  • ALTIOK S, XU M, SPIEGLEMAN BM: PPAR-y induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via downregulation of PP2A. Genes Dev. (1997) 11:1987–1998.
  • KAWA S, NIKAIDO T, UNNO H, USUDA N, NAKAYAMA K, KIYOSAWA K: Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR-y ligand troglitazone. Pancreas (2002) 24:1–7.
  • MORRISON RF, FARMER SR: Role ofPPAR-y in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Wafl/Cipl), during adipogenesis. Biol. Chem. (1999) 274:17088–17097.
  • LIU H, ZANG C, FENNER MH, POSSINGER K, ELSTNER E: PPAR-y ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res. Treat (2003) 79:63–74.
  • LU M, KWAN T, YU C et al: PPARy agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J. Biol. Chem. (2005) 280:6742–6751.
  • YIN F, BRUEMMER D, BLASCHKE F, HSUEH WA, LAW RE, HERLE AJ: Signalling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene (2004) 23:4614–4623.
  • MARGELI A, OURAKLIS G, THEOCHARIS S: Peroxisome proliferator activated receptor-y (PPAR-y) ligands and angiogenesis. Arigiogenesis (2003) 6:165–169.
  • INOUE K, KAWAHITO Y, SANO H, TAKANO H, YOSHIKAWA T: New diagnostic tool for tumour angiogenesis. Chest (2003) 123:966–967.
  • XIN X, YANG S, KOWALSKI J, GERRITSEN ME: Peroxisome proliferator-activated receptor-y ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. (1999) 274:9116–9121.
  • GOETZE S, BUNGENSTOCK A, CZUPALLA C et al.: Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR-y-ligands. Hypertension (2002) 40:748–754.
  • PANIGRAHY D, SINGERS, SHEN LQ et al.: PPAR-y ligands inhibit primary tumour growth and metastasis by inhibiting angiogenesis. Clin. Invest. (2002) 110:923–932.
  • ••PPAR-y ligands can inhibit tumourangiogenesis.
  • HUANG H, CAMPBELL SC, BEDFORD DF et al.: Peroxisome proliferator-activated receptor-y ligands improve the antitumour efficacy of thrombospondin peptide ABT510. Mal. Cancer Res. (2004) 2:541–550.
  • IJPENBURG A, TAN NS, GELMAN L et al.: hi vivo activation of PPAR target genes by RXR homodimers. EMBO (2004) 23:2083–2091.
  • WU K, ZHANG Y, XU XC et al: The retinoid X receptor-selective retinoid, LGD-1069, prevents the development of oestrogen receptor-negative mammary tumours in transgenic mice. Cancer Res. (2002) 62:6376–6380.
  • ESTEVA FJ, GLASPY J, BAIDAS S et al: Multicenter Phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin. Oncol. (2003) 21:999–1006.
  • •Large Phase II study of a rexinoid in breast cancer.
  • CROWE DL, CHANDARARATNA RA: A retinoid X receptor (RXR)-selective retinoid reveals that RXR-a is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. (2004) 6:R546–R555.
  • JAMES SY, UN F, KOLLURI SK, DAWSON MI, ZHANG XK: Regulation of retinoic acid receptor 13 expression by peroxisome proliferator-activated receptor-y ligands in cancer cells. Cancer Res. (2003) 63:3531–3538.
  • RUBIN GL, ZHAO Y, KALUS AM, SIMPSON ER: Peroxisome proliferator-activated receptor-y ligands inhibit oestrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. (2000) 60:1604-1608. ma. AANDREWS WJ, WINNETT G, REHMAN F, SHANMUGASUNDARAM P, HAGEN D, SCHREY MP: Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxypheny1)-retinamide (4HPR) is associated with enhanced ceramide production. J. Steroid Biochem. Mol. Biol. (2005) 94:159–165.
  • QIN C, BURGHARDT R, SMITH R, WORMKE M, STEWART J, SAFES: Peroxisome proliferator-activated receptor-y agonists induce proteasome-dependent degradation of cyclin D1 and oestrogen receptor-a in MCF-7 breast cancer cells. Cancer Res. (2003) 63:958–964.
  • ZHU Y, QI C, JAIN S et al.: Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc. Natl. Acad. Li. USA (1999) 96:10848–10853.
  • BUZDAR AU, IBRAHIM NK, FRANCIS D et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.Oncol(2005) (In Press).
  • PIGNATELLI M, CORTES-CANTELI M, LAI C, SANTOS A, PEREZ-CASTILLO A: The peroxisome proliferator-activated receptor-y is an inhibitor of ErbBs activity in human breast cancer cells. J. Cell Sci. (2001) 114:4117–4126.
  • HEDVAT M, JAIN A, CARSON DA et al.: Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPAR-y. Cancer Cell (2004) 5:565–74.
  • PIGNATELLI M, COCCA C, SANTOS A, PEREZ-CASTILLO A: Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor-y in the MCF-7 breast cancer cell line. Oncogene (2003) 22:5446–50.
  • BARAK Y, NELSON MC, ONG ES P et al.: PPAR-y is required for placental, cardiac, and adipose tissue development. Mol. Cell (1999) 4:585–595.
  • CUI Y, MIYOSHI K, CLAUDIO E et al: Loss of the peroxisome proliferation-activated receptor-y (PPAR-y) does not affect mammary development and propensity for tumour formation but leads to reduced fertility. Biol. Chem. (2002) 277:17830–17835.
  • JIA Y, QI C, ZHANG Z, ZHU YT, RAO SM, ZHU YJ: PBP null mutation results in defective mammary gland development. Biol. Chem. (2005) 280:10766–10773.
  • SAEZ E, ROSENFELD J, LIVOLSKI A et al.: PPAR y signalling exacerbates mammary gland tumour development. Genes Dev. (2004) 18:528–540.
  • ••PPAR-y can promote mammary tumourdevelopment in a transgenic mouse model.
  • SUH N, WANG Y, WILLIAMS CR et al: A new ligand for the peroxisome proliferator-activated receptor-y (PPAR-y), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. (1999) 59:5671–5673.
  • MEHTA RG, WLLIAMSON E, PATEL MK, KOEFFLER HP: A ligand of peroxisome proliferator-activated receptor-y, retinoids, and prevention of preneoplastic mammary lesions. J. Natl. Cancer Inst. (2000) 92:418–423.
  • MARTENS FM, VISSERAN FL, LEMAY J, DE KONING EJ, RABELINK TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs (2002) 62:1463–1480.
  • KOHLROSER J, MATHAI J, REICHHELD J, BANNER BE BONKOVSKY HL: Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. Castroenterol (2000) 95:272–276.
  • DEMETRI GD, FLETCHER CD, MUELLER E et al.: Induction of solid tumour differentiation by the peroxisome proliferator-activated receptor-y ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sri. USA (1999) 96:3951–3956.
  • DEBROCK G, VANHENTENRIJK V, SCIOT R, DEBIEC-RYCHTER M, OYEN R, VAN OOSTEROM A: A Phase II trial with rosiglitazone in liposarcoma patients. Br. J. Cancer (2003) 89:1409–1412.
  • MUELLER E, SMITH M, SARRAF P et al.: Effects of ligand activation of peroxisome proliferator-activated receptor-y in human prostate cancer. Proc. Nati Acad. Sri. USA (2000) 97:10990–10995.
  • SMITH MR, MANOLA J, KAUFMAN DS et al.: Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer (2004) 101:1569–1574.
  • •The first placebo-controlled study of a PPAR-y ligand in cancer.
  • KULKE MH, DEMETRI GD, SHARPLESS NE et al: A Phase II study of troglitazone, an activator of the PPAR-y receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. (2002) 8:395–399.
  • BURSTEIN HJ, DEMETRI GD, MUELLER E, SARRAF P, SPIEGELMAN BM, WINER EP: Use of the peroxisome proliferator-activated receptor (PPAR)-y ligand troglitazone as treatment for refractory breast cancer: a Phase II study. Breast Cancer Res. Treat (2003) 79:391–397.
  • ••First clinical trial with a PPAR-y ligand inbreast cancer.

Websites

  • Mtp://clinicaltrials.gov/ Website for ClinicalTrials.gov.
  • http://www.xartrials.de/index.php/trials/ 56.html Website for ongoing clinical trial with pioglitazone and tretinoin in breast cancer.
  • http://www.controlled-trials.com/isrctn/ Website for the ISRCTN register of clinical trials.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.